Fenwalinc

Lake Zurich, United States Founded: 1949 • Age: 77 yrs Acquired By Fresenius Kabi
Portfolio of products for transfusion medicine and cell therapy.

About Fenwalinc

Fenwalinc is a Healthcare company based in Lake Zurich (United States) founded in 1949, and was acquired by Fresenius Kabi in July 2012. Portfolio of products for transfusion medicine and cell therapy. Its Indian entity Fenwal India Private Limited reported revenue of β‚Ή10.6 Lakh. The company was acqui-hired. Its focus areas include Life Sciences, Hematology, Medical Devices and Therapeutic. Its competitors include Medcura, ExThera Medical and CytoPherx; 3 of its 3 listed competitors have raised funding.

Company details

Fenwal(acquired by Fresenius Kabi in 2012) is a blood technology company producing products to support transfusion medicine and cell therapy. Its offerings include medical technologies used in blood separation, collection, filtration, storage and transfusion. Some of its products are component collection systems, separators, and plasmapheresis systems, manual collection products, segment sampling devices, tubing sealers, sterile tube connection systems, hemoglobin screening devices, donor chairs, donor tube strippers, transfer packs, transfusion sets, platelet and cellular sample transfer kits, bone marrow kits. Fenwal Inc. was owned by Baxter Healthcare Corporation till 2007 when it was sold by Baxter to Texas Pacific Group (TPG) and Maverick Capital. In 2012, it was acquired by Fresenius Kabi

Operational Areas
Key Metrics
  • Indian entity revenue
    ₹10.6 Lakh

    FY 2019 · +1% YoY

  • Indian entity net loss
    -₹38.5 Lakh

    FY 2019 · -363% margin

  • Indian entity EBITDA
    -₹38.5 Lakh

    FY 2019 · -363% margin

  • Investors
  • Acquired by

Investors in Fenwalinc

Fenwalinc has secured backing from 1 investor. Prominent investors backing the company include Fresenius Kabi.

All
InvestorDescriptionFounded YearDomainLocation
Healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals.
1999fresenius-kabi.com
Premium access

Investor details for Fenwalinc

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Fenwal India Private Limited (Fenwalinc)

Fenwal India Private Limited is the primary company behind Fenwalinc. The board of Fenwal India Private Limited currently have 2 directors; the longest-serving is Govind Ram Cheyyur, appointed in 2014. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Govind Ram Cheyyur
DIN 06948443
Director05 Sep 201412 yrs 2 moFenwal India Private Limited
Ashish Mukund Kulkarni
DIN 06998433
Director20 Oct 201412 yrs 1 moFenwal India Private Limited

Financials of Fenwalinc

Figures of Fenwal India Private Limited, the primary company behind Fenwalinc, for FY 2019. Revenue was ₹10.6 Lakh (+1% year on year). Net loss was -₹38.5 Lakh (-363% margin). EBITDA was -₹38.5 Lakh (-363% margin). Revenue has grown at a compounded annual rate of -82% over three years.

  • ₹10.6 LakhRevenue · FY 2019 · +1% YoY
  • -₹38.5 LakhNet loss · -363% margin
  • -₹38.5 LakhEBITDA · -363% margin
  • ₹31.40 CrPaid-up capital
  • -82%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Fenwal India Private Limited are on its company page.

Premium access

Detailed financial statements for Fenwalinc

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Fenwalinc

2 dated milestones of Fenwalinc across 63 years, from founding to its latest funding, stage changes and deals.

  1. Founded Fenwalinc is founded.
  2. Exit Acquired by Fresenius Kabi.

Competitors of Fenwalinc

Fenwalinc has 3 listed competitors in our database, 3 of them funded. They include Medcura, ExThera Medical and CytoPherx.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
medcurainc.com2019United States$87.35M
Developer of the device for controlling bleeding
extheramedical.com2007Berkeley, United States$54.59M23
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
cytopherx.com1994Ann Arbor, United States$45.69M
Cytopheresis systems for inflammatory conditions
Premium access

Detailed competitors of Fenwalinc

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Fenwalinc

Websites that share an audience with Fenwalinc (fenwalinc.com).

Similar websites

Websites whose visitors overlap most with Fenwalinc. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
hemocue.us
hemocue.us
100%
–
haemonetics.com
98%
50.5K#632,767View details
terumobct.com
95%
56.6K#599,470View details
bonfils.org
bonfils.org
94%
#14,898,013–
giveapint.org
94%
#1,113,140View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 9 similar websites and full traffic analytics for Fenwalinc

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hematology

3 companies that operate in the same segment as Fenwalinc (Hematology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Catheter-based thrombectomy devices for vascular emboli removal are developed.
2011Irvine, California, United StatesUSD 51.89 MUSD 493.63 M696
Small molecules are developed to treat hematologic and musculoskeletal disorders.
2016Lexington, Kentucky, United StatesUSD 90 MUSD 244.06 M169
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
2016Menlo Park, California, United StatesUSD 300 M384
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Fenwalinc

Premium access

Complete news archive for Fenwalinc

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fenwalinc

Fenwalinc was founded in 1949.

Fenwalinc is headquartered in Lake Zurich, United States. It is registered at Lake Zurich, Illinois, United States.

The primary company behind Fenwalinc, Fenwal India Private Limited, reported revenue of β‚Ή10.6 Lakh for FY 2019, up 1% year on year.

Fenwal(acquired by Fresenius Kabi in 2012) is a blood technology company producing products to support transfusion medicine and cell therapy. Its offerings include medical technologies used in blood separation, collection, filtration, storage and transfusion. Some of its products are component collection systems, separators, and plasmapheresis systems, manual collection products, segment sampling devices, tubing sealers, sterile tube connection systems, hemoglobin screening devices, donor chairs, donor tube strippers, transfer packs, transfusion sets, platelet and cellular sample transfer kits, bone marrow kits. Fenwal Inc. was owned by Baxter Healthcare Corporation till 2007 when it was sold by Baxter to Texas Pacific Group (TPG) and Maverick Capital. In 2012, it was acquired by Fresenius Kabi.

Fenwalinc's top competitors include Medcura, ExThera Medical and CytoPherx.

Fenwalinc has 1 investor. Key investors include Fresenius Kabi.

Fenwalinc operates through Fenwal India Private Limited.

Yes. Fenwalinc was acquired by Fresenius Kabi in July 2012.

The legal entities of Fenwalinc currently have 2 directors, including Govind Ram Cheyyur, Ashish Mukund Kulkarni.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available